University of Strathclyde
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From University of Strathclyde
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly review of licensing agreements between companies and universities or other research institutions in the In Vitro Diagnostics, Medical Device, and Pharmaceutical sectors. This month’s column covers deals announced February through March 2016.
Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.
MGB Biopharma Ltd. believes it may be able to create compounds that directly kill bacteria before they ever have a chance to mutate. Its plan is to develop chemicals that bind to bacterial DNA and stop transcription of key genes. Indeed, the fi rst three letters of the company’s name stand for minor groove binders, because this is the class of drug that management aspires to develop as antibacterials.
VCs see rich exit opportunities, especially for start-ups with multiple products in their pipelines. In this issue we profile four emerging antibiotic drug developers: Cempra Pharmaceuticals, DesignMedix, Kenta Biotech and MGB Biopharma.
- Academic and Research Institutions